Risk stratification in Waldenström macroglobulinemia

Pierre Morel, Giampaolo Merlini

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Waldenström macroglobulinemia is characterized by the production of serum monoclonal IgM and lymphoplasmacytic bone marrow infiltration. At least 25% of patients are asymptomatic at diagnosis and treatment is only mandatory in cases of symptomatic disease. Beside reports on treatment results, reviewing risk assessment is another way to describe the clinical course of the disease. This information may be particularly useful when numerous treatment options are available. While the introduction of new treatment approaches reinforces the need for careful risk assessment, the identification of useful prognostic information requires prolonged follow-up in patients who have not been treated with current therapeutic options. This limitation should be taken into account when using and interpreting available prognostic information, especially survival estimates.

Original languageEnglish
Pages (from-to)187-199
Number of pages13
JournalExpert Review of Hematology
Volume5
Issue number2
DOIs
Publication statusPublished - 2012

Fingerprint

Waldenstrom Macroglobulinemia
Therapeutics
Immunoglobulin M
Bone Marrow
Survival
Serum

Keywords

  • prognosis
  • risk assessment
  • therapy design
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Hematology

Cite this

Risk stratification in Waldenström macroglobulinemia. / Morel, Pierre; Merlini, Giampaolo.

In: Expert Review of Hematology, Vol. 5, No. 2, 2012, p. 187-199.

Research output: Contribution to journalArticle

@article{091f32e8744747389b44acd512929aa2,
title = "Risk stratification in Waldenstr{\"o}m macroglobulinemia",
abstract = "Waldenstr{\"o}m macroglobulinemia is characterized by the production of serum monoclonal IgM and lymphoplasmacytic bone marrow infiltration. At least 25{\%} of patients are asymptomatic at diagnosis and treatment is only mandatory in cases of symptomatic disease. Beside reports on treatment results, reviewing risk assessment is another way to describe the clinical course of the disease. This information may be particularly useful when numerous treatment options are available. While the introduction of new treatment approaches reinforces the need for careful risk assessment, the identification of useful prognostic information requires prolonged follow-up in patients who have not been treated with current therapeutic options. This limitation should be taken into account when using and interpreting available prognostic information, especially survival estimates.",
keywords = "prognosis, risk assessment, therapy design, Waldenstr{\"o}m macroglobulinemia",
author = "Pierre Morel and Giampaolo Merlini",
year = "2012",
doi = "10.1586/ehm.11.82",
language = "English",
volume = "5",
pages = "187--199",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Risk stratification in Waldenström macroglobulinemia

AU - Morel, Pierre

AU - Merlini, Giampaolo

PY - 2012

Y1 - 2012

N2 - Waldenström macroglobulinemia is characterized by the production of serum monoclonal IgM and lymphoplasmacytic bone marrow infiltration. At least 25% of patients are asymptomatic at diagnosis and treatment is only mandatory in cases of symptomatic disease. Beside reports on treatment results, reviewing risk assessment is another way to describe the clinical course of the disease. This information may be particularly useful when numerous treatment options are available. While the introduction of new treatment approaches reinforces the need for careful risk assessment, the identification of useful prognostic information requires prolonged follow-up in patients who have not been treated with current therapeutic options. This limitation should be taken into account when using and interpreting available prognostic information, especially survival estimates.

AB - Waldenström macroglobulinemia is characterized by the production of serum monoclonal IgM and lymphoplasmacytic bone marrow infiltration. At least 25% of patients are asymptomatic at diagnosis and treatment is only mandatory in cases of symptomatic disease. Beside reports on treatment results, reviewing risk assessment is another way to describe the clinical course of the disease. This information may be particularly useful when numerous treatment options are available. While the introduction of new treatment approaches reinforces the need for careful risk assessment, the identification of useful prognostic information requires prolonged follow-up in patients who have not been treated with current therapeutic options. This limitation should be taken into account when using and interpreting available prognostic information, especially survival estimates.

KW - prognosis

KW - risk assessment

KW - therapy design

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84864076214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864076214&partnerID=8YFLogxK

U2 - 10.1586/ehm.11.82

DO - 10.1586/ehm.11.82

M3 - Article

C2 - 22475287

AN - SCOPUS:84864076214

VL - 5

SP - 187

EP - 199

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 2

ER -